one of the SPARTAN trial exclusion criteria says :
Prior treatment with: second generation androgen receptor (AR) inhibitors, other investigational AR inhibitors, or CYP17 enzyme inhibitor
Zytiga falls under this category
Eventually the drug indications will be derived from what was tested in the trial.
Where does it put all those who where treated per STAMPEDE/LATITUDE and received Zytiga who were not metastatic per SPARTAN definition (N1) ?